PRESS RELEASE published on 11/19/2025 at 08:41, 11 months 22 days ago Rapport Financier Semestriel 2025
PRESS RELEASE published on 11/18/2025 at 12:52, 11 months 23 days ago Rapport Financier Semestriel 2025
BRIEF published on 11/14/2025 at 23:10, 11 months 27 days ago MaaT Pharma : levée de fonds réussie de 9,1 millions d'euros Biotechnologie Innovation Médicale Investisseurs Microbiome Levée De Fonds
BRIEF published on 11/14/2025 at 23:10, 11 months 27 days ago MaaT Pharma: successful fundraising of 9.1 million euros Investors Biotechnology Fundraising Microbiome Medical Innovation
PRESS RELEASE published on 11/14/2025 at 23:05, 11 months 27 days ago Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...) MaaT Pharma annonce le succès de son Offre Globale de 9,1 millions d'euros pour le développement de Microbiome Ecosystem Therapies™. Levée de fonds pour Xervyteg® et MaaT033 Microbiome Ecosystem Therapies Offre Globale MaaT Pharma MaaT033 Xervyteg
PRESS RELEASE published on 11/14/2025 at 23:05, 11 months 27 days ago Inside Information / Operations of the issuer (acquisitions, sales...) MaaT Pharma successfully completes Global Offering of €9.1 million, strengthening financial position and supporting development of Microbiome Therapies for cancer patients Financial Position Global Offering MaaT Pharma Cancer Patients Microbiome Therapies
BRIEF published on 11/13/2025 at 19:45, 11 months 28 days ago Lancement d'une augmentation de capital par MaaT Pharma Augmentation De Capital Investisseurs Qualifiés Offre Globale MaaT Pharma Xervyteg® Commercialisation
BRIEF published on 11/13/2025 at 19:45, 11 months 28 days ago MaaT Pharma launches a capital increase Capital Increase Qualified Investors MaaT Pharma Global Offer Xervyteg® Marketing
PRESS RELEASE published on 11/13/2025 at 19:40, 11 months 28 days ago Informations privilégiées / Autres communiqués MaaT Pharma lance une augmentation de capital de 9 millions d'euros pour financer son développement. Offre d'actions nouvelles aux investisseurs. Projets de développement clinique et commercialisation Développement Augmentation De Capital Commercialisation Actions Nouvelles MaaT Pharma
Published on 11/12/2026 at 01:40, 4 hours 6 minutes ago Nexteer Announces First Share Repurchase Programme of Up to US$60 Million
Published on 11/11/2026 at 23:30, 6 hours 16 minutes ago Faraday Copper Reports Third Quarter 2026 Financial Results and Announces Changes to the Board of Directors
Published on 11/11/2026 at 23:05, 6 hours 41 minutes ago Vox Royalty Reports Q3 2026 Results and Declares Quarterly Dividend
Published on 11/11/2026 at 23:00, 6 hours 46 minutes ago CCL Industries Announces Appointment of New Director
Published on 11/11/2026 at 22:30, 7 hours 16 minutes ago 55 North Gold Qualifies for Trading on the OTCQB Venture Market and Launches New Corporate Website
Published on 11/12/2026 at 02:20, 3 hours 25 minutes ago Nanjing Offers a Window into the Yangtze River's Cultural Heritage and Renewal
Published on 11/11/2026 at 19:29, 10 hours 16 minutes ago EQS-Adhoc: Allianz SE: Allianz delivers record nine-month result of 14.1 billion euros and raises 2026 outlook
Published on 11/11/2026 at 18:41, 11 hours 4 minutes ago AUSTRIACARD HOLDINGS AG: 9M 2026 Financial Results
Published on 11/10/2026 at 18:00, 1 day 11 hours ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 1 day 12 hours ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 1 day 12 hours ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 1 day 12 hours ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
